Drug Profile
Neurokinin 1 antagonist - Nippon-Roche
Alternative Names: NK-1 antagonist - Nippon-RocheLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Chugai Pharmaceutical
- Class
- Mechanism of Action Neurokinin 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Major depressive disorder
Most Recent Events
- 31 Jul 2006 No development reported - Phase-I for Depression in Japan (unspecified route)
- 30 Oct 2002 Nippon Roche has been merged into Chugai Pharmaceutical
- 12 Jun 2002 Phase-I clinical trials in Depression in Japan (unspecified route)